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disease	aetiology	 is	poorly	understood,	 it	has	been	 linked	to	the	host	gut	microbiome,	
alongside	a	range	of	host	genetic	and	environmental	factors.	Temporary	Crohn’s	disease	
remission	 can	 be	 induced	 by	 exclusive	 enteral	 nutrition,	 which	 has	 previously	 been	





enteral	 nutrition	 on	 the	 gut	 microbiomes	 of	 both	 adult	 Crohn’s	 disease	 patients	 and	
healthy	 controls.	 Exclusive	 enteral	 nutrition	 altered	 beta	 diversity	 and	 taxonomic	
composition,	as	well	as	functional	capacity	and	short-chain	fatty	acid	production,	within	
both	Crohn’s	disease	and	healthy	gut	microbiomes.	Perturbation	of	species	belonging	to	
the	 Clostridia	 class	 dominated	 the	 taxonomic	 changes	 observed	 both	 with	 Crohn’s	
disease,	 and	 during	 exclusive	 enteral	 nutrition.	 	 These	 changes	 were	 predominantly	
transient,	with	the	gut	microbiomes	of	both	Crohn’s	disease	patients	and	healthy	people	
largely	 rebounding	 after	 treatment.	 There	 were	 no	 changes	 to	 the	 gut	 microbiome	
observed	during	partial	 enteral	nutrition,	 and	no	 changes	 in	alpha	diversity	observed	
during	any	form	of	enteral	nutrition.	Exclusive	enteral	nutrition	reduced	the	capacity	of	
the	 gut	microbiome	 to	 produce	 flagella,	 through	 perturbation	of	 species	 belonging	 to	
Clostridium	 cluster	XIVa.	Through	analysis	of	 the	 role	played	by	 commensal	Clostridia	
class	species	 in	 the	guts	of	Crohn’s	disease	patients,	 a	novel	model	of	Crohn’s	disease	
aetiology	was	developed,	implicating	Clostridium	cluster	XIVa	flagellin	proteins	CBir1	and	
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UC	 patients	 per	 100,000	 people,	 and	 observed	 incidence	 rates	 greater	 than	 6.38	 CD	
patients	and	7.71	UC	patients	per	100,000	person-years	in	these	regions	(Ng	et	al.,	2018).	









and	 environment	 (Kaplan	 and	 Ng,	 2017).	 With	 increasing	 IBD	 prevalence,	
implementation	of	strategies	and	treatments	to	manage	the	increasing	disease	burden	is	
imperative.	 As	 there	 is	 no	 treatment	 currently	 available	 that	 induces	 permanent	 IBD	
remission,	development	of	further	treatments	may	be	a	viable	way	of	achieving	this	goal	
(Pillai	et	al.,	2019).	
1.2 Clinical presentation of inflammatory bowel disease 
While	 exact	 IBD	 symptoms	 are	 dependent	 on	 both	 the	 severity	 and	 location	 of	
inflammation,	 these	 typically	 include	 chronic	 diarrhoea	 and	 abdominal	 pain	
(Hendrickson	et	al.,	2002).	Other	symptoms	may	include	fever,	weight	loss,	osteoporosis,	
and	 stunted	 growth	 in	 children	 (Hendrickson	 et	 al.,	 2002).	 Symptoms	 typically	 go	
through	 periods	 of	 dormancy,	 with	 subsequent	 inflammatory	 flare-ups	 (Lewis	 et	 al.,	
2004).	 IBD	 has	 also	 been	 associated	 with	 an	 increased	 risk	 of	 colorectal	 cancer,	
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particularly	 in	 patients	 who	 have	 suffered	 from	 severe	 and	 prolonged	 inflammation	
(Terzic	et	al.,	2010).	
While	both	CD	and	UC	display	similar	inflammatory	symptoms,	some	variation	in	clinical	










1.3 Crohn’s disease associated risk factors 
1.3.1 Host genetic factors in Crohn’s disease 
While	the	exact	aetiology	of	CD	is	currently	unknown,	CD	has	been	linked	to	a	number	of	
risk	factors,	both	within	the	host	and	from	the	environment.	Host	factors	linked	to	CD	
include	 host	 genetics,	 and	 the	 host’s	 gut	microbiome	 (Jostins	 et	 al.,	 2012;	 Rogler	 and	
Hausmann,	2019).	The	greatest	risk	factor	for	developing	CD	is	a	family	history	of	IBD.	
Gearry	 et	 al.	 (2010)	 demonstrated	 that	 1	 family	 member	 known	 to	 have	 had	 IBD	
significantly	increased	CD	risk	(CD	odds	ratio,	OR:	3.06	[95%	confidence	interval,	CI:	2.18	





repeated	 investigation	 of	 CD	 concordance	 in	 twins.	 Multiple	 studies,	 across	 multiple	
populations,	have	demonstrated	that	monozygotic	twins	have	a	significantly	higher	rate	
of	CD	concordance	than	dizygotic	twins	(OR:	4.34	-	25)	(Halfvarson	et	al.,	2003;	Ng	et	al.,	
2012;	 Spehlmann	 et	 al.,	 2008).	 Despite	 a	 large	 range	 of	 effect	 sizes,	 the	 significantly	
increased	 risk	 of	 CD	 concordance	 in	 monozygotic	 twins	 relative	 to	 dizygotic	 twins	
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Prior	 host	 genetic	 studies	 have	 suggested	 that	 CD	 inflammation	 is	 resultant	 from	 an	
aggravated	response	from	T-helper-1	(TH1)	and	T-helper-17	(TH17)	cells	within	the	gut	
mucosal	 immune	 system,	 mediated	 by	 the	 IL-12/IFN-γ/TNF	 cytokine	 axis	 and	 IL-17	





containing	 protein	 2	 (NOD2),	 previously	 known	 as	 caspase	 recruitment	 domain-
containing	protein	15	(CARD15)	(Hugot	et	al.,	2001;	Ogura	et	al.,	2001).	NOD2	belongs	to	
the	 pattern	 recognition	 receptor	 (PRR)	 family,	 and	 responds	 to	 bacterial	 muramyl	
dipeptide	(Girardin	et	al.,	2003).	As	a	member	of	the	PRR	family,	NOD2	is	known	to	be	
involved	in	the	mediation	of	inflammatory	cytokine	release	(Takeuchi	and	Akira,	2010).	
However,	 the	 exact	 role	 of	 NOD2	 in	 CD	 aetiology	 is	 currently	 not	 well	 understood	
(Mukherjee	et	al.,	2018).	Despite	this	uncertainty,	associations	between	polymorphisms	








1.3.2 Environmental factors in Crohn’s disease 
As	classical	twin	studies	comparing	monozygotic	and	dizygotic	twins	have	been	utilised	
to	demonstrate	a	link	between	host	genetics	and	CD,	comparison	of	CD	concordance	in	
dizygotic	 twin	 and	 non-twin	 siblings	 suggests	 an	 environmental	 contribution	 to	 CD.	
Bengtson	 et	 al.	 (2010)	 demonstrated	 that,	 while	 both	 dizygotic	 twins	 and	 non-twin	
siblings	have	a	substantially	increased	rate	of	CD	concordance	relative	to	that	expected	














antibiotic	 treatments	 has	 been	 hypothesised	 as	 the	 mechanism	 by	 which	 CD	 risk	 is	
increased	 (Card	 et	 al.,	 2004;	Kronman	 et	 al.,	 2012).	 Alteration	of	 the	 gut	microbiome	





Environmental	 factors	 that	 alter	 the	 gut	microbiome	 through	 less	 direct	mechanisms	
have	also	been	linked	to	increased	CD	risk.	These	include	smoking	(CD	OR:	1.99	[95%	CI:	
















that	 associated	environmental	 changes	play	a	 significant	 role	 in	CD	pathogenesis.	The	
hygiene	hypothesis	proposes	that	a	combination	of	reduced	infection	rates,	vaccination,	
and	 improved	 sanitation	 over	 time	 have	 resulted	 in	 loss	 of	 sensitivity	 to	 important	
immunomodulatory	antigenic	signals,	thus	contributing	to	the	risk	of	diseases	such	as	CD	







Sakamoto	et	 al.,	 2005).	These	dietary	 changes	alter	both	 the	gut	microbiome,	 and	 the	







1.4 The gut microbiome in health and disease 
1.4.1 Gut microbiome function 
The	human	microbiome	is	substantial,	containing	more	than	1013	bacterial	cells,	similar	
to	 the	 number	 of	 human	 host	 cells	 (Sender	 et	 al.,	 2016).	 This	 vast	 community	 plays	
numerous	 important	 roles	 in	 health	 and	 disease,	 through	 both	 direct	 and	 indirect	






Colonisation	of	 the	gut	microbiome	begins	at	birth,	when	 the	 infant	 is	 exposed	 to	 the	
mother’s	vaginal,	faecal,	and	skin	microbiome	(Palmer	et	al.,	2007).	From	this	point,	the	
human	 microbiome	 evolves	 over	 the	 course	 of	 the	 host’s	 life,	 modified	 by	 both	
endogenous	and	exogenous	factors.	These	factors	include	host	genetics	and	diet,	among	
many	 others	 (David	 et	 al.,	 2014;	 Goodrich	 et	 al.,	 2014;	 Rothschild	 et	 al.,	 2018).	 This	
combination	 of	 selective	 pressures	 results	 in	 a	 normal	 microbiota	 that	 varies	
substantially	between	hosts,	and	between	body	sites	on	a	single	host	(Falony	et	al.,	2016).	
The	majority	of	 inter-host	gut	microbiome	variability	occurs	at	 the	genus	and	species	
level,	 with	 the	 gut	microbiomes	 of	most	 people	 dominated	 by	 the	 Bacteroidetes	 and	
Firmicutes	phyla	(Lozupone	et	al.,	2012b).	
Large-scale	projects,	such	as	 the	Human	Microbiome	Project	(HMP)	and	the	European	
MetaHIT	 (Metagenomics	of	 the	Human	 Intestinal	Tract)	project,	have	endeavoured	 to	
define	 the	 role	 of	 the	 human	microbiome	 in	 health	 and	 disease	 through	multi-“omic”	
approaches	(Huttenhower	et	al.,	2012;	Qin	et	al.,	2010).	While	there	is	still	much	work	to	








the	 substantial	 GI	 tract	 surface	 area	 (Helander	 and	 Fandriks,	 2014).	 The	 normal	 gut	
microflora	 also	 has	 a	 protective	 effect,	with	 competitive	 exclusion	 by	 the	 pre-existing	
microbes	creating	a	physical	barrier	against	incoming	pathogens	(Sekirov	et	al.,	2010).	
Associations	have	also	been	made	between	the	gut	microbiome	and	numerous	aspects	of	
host	 physiology	 outside	 the	 gut,	 including	 changes	 in	 metabolism	 and	 behaviour	
(Sommer	and	Backhed,	2013).	
In	order	for	the	gut	microbiome	to	be	beneficial	to	host	health,	community	homeostasis	
must	 be	maintained.	While	 the	 healthy	 adult	 gut	microbiome	 is	 believed	 to	 be	 highly	




and	Garrett,	2016).	Through	 this,	dysbiosis	may	cause	disease	 in	 the	host	 (Lyons	and	
Coopersmith,	2017).		
1.4.2 Crohn’s disease and the gut microbiome 
It	is	well	accepted	that	an	inappropriate	immune	response	at	the	host	mucosa	in	response	
to	 the	 gut	microbiome	 is	 a	 probable	 cause	 of	 CD	 (Kostic	 et	 al.,	 2014).	 This	 has	 been	









(Mizoguchi,	2012).	These	methods	 include	 chemical	 induction,	 cell-transfer,	 congenial	













2006).	 Antibiotics	 used	 for	 CD	 treatment	 are	 typically	 broad-spectrum,	 including	
metronidazole	and	ciprofloxacin	(Bernstein,	2013).	When	considered	with	the	increased	
CD	risk	associated	with	antibiotic	use	at	different	life	stages,	this	supports	the	hypothesis	
that	 host	 microbiome	 dysbiosis	 contributes	 to	 CD,	 with	 antibiotic	 treatment	 able	 to	
remediate	this	in	some	cases	(Card	et	al.,	2004;	Kronman	et	al.,	2012).	
While	there	is	substantial	variation	between	studies,	the	CD	gut	microbiome	is	broadly	





al.,	 2005).	 As	 such,	 it	 has	 been	 speculated	 that	 it	 may	 be	 preferable	 to	 primarily	
investigate	 the	 composition,	 genetic	 capacity,	 and	 interactions	 within	 the	 gut	
microbiome,	as	opposed	to	focussing	on	individual	species	(Ley	et	al.,	2008;	Tringe	et	al.,	
2005).	These	measures	give	a	broader	view	of	community	characteristics.	 In	 this	way,	
both	 interpersonal	 variation	 and	 functional	 redundancy	 can	 be	 accounted	 for,	 and	
differences	in	the	impact	of	the	gut	microbiome	on	the	host	can	be	more	clearly	assessed.	
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This	 impact	 can	 include	 direct	 host	 interaction	with	microbial	 antigens,	 and	 immune	
regulation	by	microbial	metabolites.	
1.5 Regulation of immune responses 
1.5.1 Regulatory T cells in immunological tolerance 
The	link	between	a	TH1/TH17	immune	response	and	CD	aetiology	implies	that	CD	is	also	
linked	to	Treg	cell	activity.	Treg	cells	are	a	sub-population	of	CD4+	T	cells	that	express	the	
transcription	 factor	 FoxP3,	 and	 are	 proposed	 to	 suppress	 an	 effector	 T	 cell	 response	
through	the	production	of	anti-inflammatory	cytokines	such	as	IL-10	(Hori	et	al.,	2003;	
Sakaguchi	et	al.,	2001;	Stewart	et	al.,	2013).	Treg	cells	have	been	heavily	implicated	in	the	





peripheral	 regulatory	 T	 (pTreg)	 cell	 differentiation	 in	 this	 area.	 This	 association	 is	





It	 has	 also	 been	 demonstrated	 that	 adoptive	 transfer	 of	 Treg	 cells	 into	 colitic	 mouse	
models	reduces	inflammation	through	downregulation	of	the	TH17	response	(Harrison	et	
al.,	2015).	
1.5.2 Short-chain fatty acids modulate regulatory T cell differentiation 
The	 close	 association	 of	 the	 gut	 microbiome	 with	 the	 intestinal	 epithelia	 allows	
substantial	interaction	with	the	host.	Microbial	metabolites,	including	short-chain	fatty	
acids	(SCFAs),	contribute	substantially	to	this	interaction.	SCFAs	are	products	of	bacterial	
fermentation,	 and	 influence	 the	generation	of	Treg	 cells	 (Morrison	and	Preston,	2016).	










cells,	 and	prevent	 conversion	of	 naïve	T	 cells	 into	 pro-inflammatory	T	 cells	 (IFN-γ+	 T	
cells)	(Gurav	et	al.,	2015).	
It	 has	 been	 demonstrated	 that	 butyrate	 activation	 of	 the	 G	 protein	 coupled	 receptor	








the	differentiation	of	naïve	T	cells	 to	pTreg	cells	both	in	vitro	and	 in	vivo	 (Arpaia	et	al.,	
2013).	 The	 mechanism	 proposed	 for	 this	 SCFA	 action	 was	 through	 the	 inhibition	 of	













However,	 to	 best	understand	 the	 role	 of	 the	 gut	microbiome	 in	 CD,	 other	methods	of	
controlling	CD	inflammations	and	altering	the	gut	microbiome	must	first	be	understood.	
1.6 Treatment of Crohn’s disease 
1.6.1 Traditional Crohn’s disease therapies 





inflammation	 is	 reduced	 using	 corticosteroids	 including	 prednisone,	 budesonide,	 and	
hydrocortisone	acetate	(Cronin,	2010;	Farrell	et	al.,	2003;	Greenberg	et	al.,	1994).	The	
observed	 efficacy	 of	 corticosteroid	 treatment	 of	 Crohn’s	 disease	 inflammation	 varies	
between	studies	and	dosages,	with	prednisone	inducing	remission	in	60%-92%	of	active	
CD	 patients,	 and	 budesonide	 inducing	 remission	 in	 47%-69%	 of	 active	 CD	 patients	
(Malchow	 et	 al.,	 1984;	Mowat	 et	 al.,	 2011;	 Rezaie	 et	 al.,	 2015;	 Summers	 et	 al.,	 1979).	
However,	only	44%	of	CD	patients	demonstrate	prolonged	remission	1	year	after	steroid	
treatment,	while	 36%	exhibit	 steroid	 dependency	 and	 20%	exhibit	 steroid	 resistance	
(Munkholm	 et	 al.,	 1994).	 Corticosteroids	 prescribed	 for	 CD	 patients	 can	 also	 have	
significant	 side	 effects,	 including	high	 blood	 pressure,	 high	 blood	sugar,	osteoporosis,	
cataracts,	 a	weakened	 immune	 system,	 and	 Cushing’s	 syndrome	 (Barnes	 and	Adcock,	
2009;	Manson	et	al.,	2009).	Because	of	this,	corticosteroids	are	ideally	only	prescribed	for	


















remained	 uncontrollable	 by	 other	 treatment	methods.	 In	 cases	where	 portions	 of	 the	
intestine	have	become	damaged	due	to	severe	inflammation,	these	may	be	removed	by	
resection	(Simillis	et	al.,	2008).	Surgical	drainage	procedures	may	also	be	used	to	treat	
abscesses	 around	 the	 anus	 (Faucheron	 et	 al.,	 1996).	 However,	 even	 with	 surgical	
treatment,	most	patients	will	 eventually	 relapse,	with	 reoperation	 rates	 ranging	 from	
40%	to	80%	of	patients	(Bernell	et	al.,	2000;	Olaison	et	al.,	1992).	The	inefficiency	and	
substantial	 negative	 side	 effects	 of	 current	 CD	 treatments	 mean	 that	 an	 improved	
treatment	method	is	required.		
1.6.2 Exclusive enteral nutrition 
In	children,	exclusive	enteral	nutrition	(EEN)	is	commonly	used	as	a	CD	treatment	(Day	
and	 Lopez,	 2015).	 EEN	 is	 a	 form	 of	 therapeutic	 nutrition,	 in	which	 the	 patient’s	 diet	




EEN	 tends	 to	 be	 safer	 for	 patients	 than	 other,	 traditional	 CD	 treatments,	 such	 as	
immunomodulators	 or	 corticosteroids	 (Kansal	 et	 al.,	 2013;	Manson	 et	 al.,	 2009).	 It	 is	
effective	at	inducing	remission	in	approximately	85%	of	paediatric	CD	cases,	and	meta-




healing	 of	mucosal	 damage	 resultant	 from	CD,	 but	 this	 has	 not	 yet	 been	 conclusively	
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CD	cases,	 there	has	been	 less	evidence	of	 this	efficacy	 in	adult	patients	 (Ashton	et	 al.,	
2019).	Meta-analysis	 suggests	 that	 this	 is	 unlikely	 to	 be	 due	 to	 a	 differing	 treatment	
mechanism	 in	 adults,	 but	 rather	 due	 to	 low	 adult	 treatment	 compliance,	 due	 to	 poor	
formula	 taste	 (Wall	 et	 al.,	 2013).	 In	 paediatric	 CD	 cases,	 compliance	 to	 the	 full	 EEN	
treatment	has	been	demonstrated	to	range	from	56%-93%	of	participants	(Gavin	et	al.,	
2005;	Whitten	 et	 al.,	 2012).	 In	 a	meta-analysis	 of	 EEN	 treatment	 studies	 on	 adult	 CD	
patients,	 full	 treatment	 compliance	 ranged	 as	 low	 as	 59%	of	 participants	 (Wall	 et	 al.,	





be	 learned	 regarding	 best	 practices	 for	 its	 administration.	 This	 includes	 determining	
efficacy	of	enteral	nutrition	as	an	exclusive	diet,	compared	to	as	part	of	a	slightly	more	
inclusive	diet,	or	partial	enteral	nutrition	(PEN),	which	allows	the	consumption	of	some	
foods	 other	 than	 the	 enteral	 nutrition	 (EN)	 formula	 (Shah	 and	 Kellermayer,	 2014).	
Further	knowledge	of	the	EN	mechanism	of	action	would	assist	in	this	optimisation.	
Several	 small	 case	 studies	 have	 indicated	 that	 EEN	 alters	 the	 gut	 microbiome	 of	 CD	
patients	 (Leach	 et	 al.,	 2008;	 Lionetti	 et	 al.,	 2005).	However,	 despite	 these	 studies,	 no	
single	taxon	has	been	conclusively	linked	to	CD,	or	EEN	treatment	(Shah	and	Kellermayer,	
2014).	Beyond	altering	an	imbalanced	gut	microbiome	in	CD	patients,	paediatric	studies	




mucosal	 healing,	 through	 reduction	 of	 permeability	 in	 the	 dysfunctional	 intestinal	
epithelia	of	CD	patients	(Nahidi	et	al.,	2014;	Shah	and	Kellermayer,	2014).		
The	mechanism	by	which	EEN	is	therapeutic	in	CD	cases	is	not	well	understood.	There	
have	 been	 several	 hypotheses	 posed	 as	 to	 how	EEN	 exerts	 this	 therapeutic	 response,	
including	 general	 nutritional	 repletion,	 or	 reduction	 in	 inflammatory	 by-products	
produced	by	the	provision	of	complex	dietary	fats	or	carbohydrates	(Critch	et	al.,	2012;	
Nahidi	et	al.,	2014).	It	has	also	been	hypothesised	that	the	EEN	therapeutic	response	is	
due	 to	 a	 reduction	 in	 exposure	 to	 antigens,	 or	 an	 improvement	 in	 intestinal	 barrier	
function	(Critch	et	al.,	2012;	Nahidi	et	al.,	2014).	
1.7 Microbial community analysis 
1.7.1 Sequencing microbial communities 
As	it	is	impossible	to	apply	in	vitro	cultivation	techniques	to	many	microbial	communities,	
including	 the	 gut	 microbiome,	 modern	 studies	 investigating	 microbial	 communities	
typically	 utilize	 DNA	 sequencing	 techniques	 (Amann	 et	 al.,	 1995).	 These	 DNA-based	
analyses	 have	 revolutionised	 the	 study	 of	 microbial	 communities	 in	 numerous	
environments,	 and	 have	 generated	 vast	 databases	 which	 may	 be	 utilised	 to	 give	
information	on	numerous	microbial	species	(DeSantis	et	al.,	2006;	Quast	et	al.,	2013).		
The	 most	 common	 method	 for	 observing	 the	 composition	 of	 microbial	 communities	
involves	 sequencing	 the	 ubiquitous	 gene	 encoding	 16S	 ribosomal	 ribonucleic	 acid	





Here,	 the	 hyper-conserved	 regions	 allow	 for	 universal	 16S	 rRNA	 gene	 sequence	

















In	 gut	 microbiome	 analysis,	 the	 microbial	 community	 present	 in	 stool	 samples	 is	
commonly	sequenced	(Panek	et	al.,	2018).	This	allows	for	non-invasive	observation	of	
gut	microbiome	composition.	
1.7.2 Quantifying microbial community characteristics 
When	 comparing	human	microbiome	 samples,	 there	 is	 a	huge	degree	 of	 species-level	




appropriate	 in	microbiome	studies	 to	analyse	changes	 in	community	composition	and	
functionality,	 as	 opposed	 to	 changes	 in	 the	 abundance	 of	 individual	 species.	 This	 can	
include	analysis	of	 the	ecological	properties	of	 the	community,	such	as	alpha	and	beta	
diversity,	as	well	as	genetic	functions	within	the	community.	
1.8 Study aims 












This	 will	 test	 the	 hypotheses	 that	 EN	 treatment	 alters	 SCFA	 production	 by	 the	 gut	
microbiomes	of	CD	patients,	and	that	this	production	becomes	more	like	that	of	the	gut	
microbiomes	of	healthy	people.	










A	 cohort	 of	 CD	 patients	 and	 healthy	 controls	 was	 recruited	 and	 stool	 samples	 were	
collected	by	the	Gearry	and	Day	research	groups,	at	the	University	of	Otago	Christchurch.	
Samples	were	stored	at	-80	℃	until	DNA	extraction.	CD	patients	aged	16	to	40	years	old,	


















formula	 and	water	 for	 the	 first	 2	weeks	 of	 their	 8-week	 EN	 treatment	 time.	 For	 the	


















Figure	 1.	 Timeline	 of	 EN	 treatment	 for	 EEN,	 PEN,	 and	 healthy	 control	 groups.	
Treatments	 and	 follow-up	stages	 are	 represented	 by	 timeline	 colours.	 Stool	 sampling	
timepoints	 are	 represented	 by	 diamonds.	 Jumps	 in	 time	 are	 represented	 by	 jagged	
portions	of	the	timeline.
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2.2 Stool sample data collection 















2.2.2 Gas chromatography of cohort stool samples 
The	same	subset	of	90	EEN	and	healthy	control	stool	samples	that	underwent	WGS	(Table	
S2)	 also	 underwent	 SCFA	 content	 measurement	 by	 gas	 chromatography.	 Gas	






2.3 Bioinformatic analysis 






2.3.1 Taxonomic assignment of 16S rRNA gene sequences 
The	dada2	R	package	was	used	to	assign	amplicon	sequence	variants	(ASVs)	to	16S	rRNA	
gene	 reads	 across	 all	 samples	 (Callahan	 et	 al.,	 2016).	 ASVs	 are	 similar	 to	 operational	






reads,	 for	 all	 samples.	 Here,	 median	 sequence	 nucleobase	 Phred	 quality	 scores	 were	













and	 reverse	 reads	 to	 give	 full	 sequence	 contigs.	Merged	 sequences	were	 only	 output	







contributing	 sequences.	 The	 total	 number	 of	 reads	 passing	 each	 stage	 of	 the	dada2	
pipeline	to	this	point	was	tracked	in	6	samples.	
The	dada2	 functions	assignTaxonomy	 and	addSpecies	were	 then	used	 to	assign	
genus-	 and,	where	 possible,	 species-level	 taxonomy	 to	 the	 ASVs	 using	 the	 Ribosomal	
Database	Project	(RDP)	naïve	Bayesian	classifier	method	(Wang	et	al.,	2007).	Both	the	
assignTaxonomy	and	addSpecies	functions	assigned	taxonomy	based	on	the	SILVA	
132	 rRNA	 reference	 database.	 The	 ASV	 and	 taxonomic	 tables	 produced	with	dada2,	
along	with	all	sample	metadata,	were	imported	for	further	analysis	with	the	phyloseq	
R	package	(McMurdie	and	Holmes,	2013).	




2.3.2 Community alpha diversity analysis 
2.3.2.1 Alpha diversity metrics 
Alpha	diversity	of	16S	rRNA	data	from	stool	samples	was	quantified	by	observed	species	
richness,	Shannon	index,	and	Gini-Simpson	index.	The	species	richness	of	a	community	is	
defined	 as	 the	 number	 of	 species	 present	 in	 that	 community	 (Lande,	 1996).	 Shannon	
information	quantifies	entropy,	or	the	degree	of	uncertainty,	within	a	population,	and	can	
therefore	be	used	to	quantify	community	richness	based	on	relative	species	abundance	
(Lande,	 1996;	 Shannon	 and	 Weaver,	 1949).	 The	 Simpson	 concentration,	 &,	 is	 the	
probability	 that	2	 individuals	 chosen	randomly	 from	a	given	population	belong	 to	 the	
same	group	(Simpson,	1949).	Therefore,	1 − 	&,	otherwise	known	as	the	Gini	coefficient	
or	 Gini-Simpson	 index,	 is	 the	 probability	 that	 2	 individuals	 randomly	 chosen	 from	 a	
population	belong	to	different	groups,	which	may	also	be	used	as	a	measure	of	ecological	
diversity	(Pielou,	1969).	










S1).	 This	 rarefaction	 curve	 was	 analysed	 to	 determine	 optimal	 rarefaction	 depth,	
balancing	 reliable	 observation	 of	 species	 richness	with	minimal	 loss	 of	 samples.	 The	
optimal	rarefaction	depth	for	the	tested	samples	was	determined	to	be	15,000	reads.	
2.3.2.3 Comparison of community alpha diversity 
Alpha	diversities	within	communities	were	compared	across	both	disease	state	and	EN	















Kruskal-Wallis	 tests	 and	a	post-hoc	pairwise	Wilcoxon	rank	 sum	test	with	Benjamini-
Hochberg	correction	were	used.	
2.3.3 Community beta diversity analysis 
2.3.3.1 Beta diversity metrics 
Beta	diversity	between	stool	samples	was	quantified	 in	16S	rRNA	data	by	Bray-Curtis	
dissimilarity,	 and	 both	 weighted	 and	 unweighted	 UniFrac	 distance.	 Bray-Curtis	
dissimilarity	 quantifies	 differences	 between	 communities	 based	 on	 taxonomic	
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composition,	 but	 not	 the	 phylogenetic	 relatedness	 of	 observed	 taxa	 (Bray	 and	Curtis,	
1957).	UniFrac	distance	 is	 another	measure	of	 relatedness	between	communities,	but	








2.3.3.2 Phylogenetic tree construction 
Computation	 of	 both	 weighted	 and	 unweighted	 UniFrac	 distances	 requires	 the	
construction	 of	 a	 phylogenetic	 tree,	 to	 provide	 information	 on	 the	 phylogenetic	
relatedness	 of	 all	 species	 observed	 in	 samples.	 The	 DECIPHER	 R	 package	 function	
AlignSeqs	was	used	to	align	sample	DNA	sequences	(Wright,	2016).	The	phangorn	R	
package	function	modelTest	was	used	to	determine	which	DNA	substitution	model	best	
fits	 the	 aligned	 DNA	 sequences,	 to	 allow	 for	 distance	 between	 DNA	 sequences	 to	 be	
computed	 using	 maximum	 likelihood	 methodology	 (Table	 S3)	 (Felsenstein,	 1981;	
Schliep,	2011).	The	optimal	DNA	substitution	model	was	determined	based	on	Akaike	
information	 criterion	 (AIC),	 with	 a	 lower	 AIC	 value	 indicating	 better	 model	 fit,	 and	
therefore	an	optimal	substitution	model	for	the	available	DNA	sequences	(Akaike,	1974).	
Based	on	this	analysis,	the	optimal	tested	DNA	substitution	model	was	determined	to	be	
the	 Hasegawa,	 Kishino,	 and	 Yano	 (HKY)	 model,	 assuming	 gamma-distributed	 rate	
variation	(“HKY	+	G”	model)	(Hasegawa	et	al.,	1985).	
The	phangorn	function	bootstrap.pml	was	used	to	bootstrap	the	“HKY	+	G”	model	
phylogenetic	 tree	 100	 times,	 with	 bootstrapped	 support	 values	 representing	 the	
frequency	of	re-observation	of	the	same	phylogenetic	branch.	The	phangorn	 function	
plotBS	 was	 then	 used	 to	 create	 a	 “HKY	 +	 G”	 model	 phylogenetic	 tree,	 containing	
branches	 with	 bootstrapped	 support	 values	 greater	 than	 80%.	 This	 bootstrapped	
phylogenetic	tree	was	then	imported	with	phyloseq	for	further	analysis.	
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2.3.3.3 Comparison of community beta diversity clusters 
The	 relationships	 between	 disease	 state,	 EN	 treatment,	 time	 and	 stool	 sample	 beta	
diversity	were	quantified	using	Kruskal’s	nonmetric	multidimensional	 scaling	 (NMDS)	
(Kruskal,	 1964).	 Stool	 sample	 16S	 rRNA	 data	were	 subset	 by	whether	 samples	were	
collected	before	EN	treatment,	and	whether	they	were	collected	from	the	EEN,	PEN,	or	
healthy	 control	 groups.	 The	 vegan	 R	 package	 function	 metaMDS	 was	 used	 to	
independently	perform	NMDS	with	20	random	starting	configurations	on	the	subset	of	
samples	 collected	before	EN	 treatment,	 and	 the	 subsets	of	 samples	 collected	 from	 the	
EEN,	PEN,	 and	healthy	 control	 groups	 (Oksanen	et	 al.,	 2018).	NMDS	was	utilised	with	













and	 healthy	 control	 subsets,	 pairwise	 PERMANOVA	 with	 999	 permutations	 and	
Benjamini-Hochberg	correction	was	used	to	directly	compare	groups.	
2.3.4 Taxonomic assignment of whole genome sequences 
The	BBMap	program	function	demuxbyname	was	used	to	demultiplex	all	WGS	reads	into	






2.3.5 Genetic pathway assignment within whole genome sequences 
The	pipeline	HUMAnN2	was	used	to	determine	the	abundance	of	genetic	pathways	within	
each	 microbial	 community	 sample	 (Franzosa	 et	 al.,	 2018).	 This	 includes	 the	 total	
abundance	 of	 pathways	 across	 all	 species	 in	 a	 community,	 and	 the	 abundance	 of	
pathways	within	attributable	 species.	HUMAnN2	was	used	 to	 identify	UniRef50	genes	
present	in	sample	reads,	which	were	then	associated	with	specific	organisms	based	on	
the	 MetaPhlAn2	 taxonomic	 profiles.	 HUMAnN2	 was	 then	 used	 to	 group	 identified	
UniRef50	 genes	 into	 genetic	 pathways.	 These	 UniRef50	 pathway	 names	 were	 then	
translated	to	Kyoto	Encyclopaedia	of	Genes	and	Genomes	(KEGG)	pathway	names.	
2.3.6 Identification of differentially expressed community tags 
The	R	package	edgeR	was	used	to	analyse	changes	in	the	abundance	of	both	individual	
bacterial	 species	 and	 individual	 KEGG	 pathways	 over	 the	 course	 of	 EN	 treatment	
(Robinson	et	 al.,	 2010).	 Samples	were	grouped	based	on	whether	 they	were	 collected	
from	the	EEN	or	healthy	control	groups,	and	whether	they	were	collected	before,	during,	
or	 after	 EN	 treatment.	 All	 tags,	 here	 defined	 as	 either	 the	 bacterial	 species	 or	 KEGG	
pathway	to	be	investigated,	were	filtered	out	where	not	present	at	a	minimum	of	1	count	
per	million	(CPM)	in	at	least	6	of	the	samples	in	each	group.	Normalisation	factors	were	
calculated	using	 the	 trimmed	mean	of	M-values	 (TMM)	method,	 and	raw	 library	sizes	
were	scaled	accordingly	(Robinson	and	Oshlack,	2010).	Negative	binomial,	and	adjusted	
profile	log-likelihoods	were	maximised,	and	estimates	of	common,	trended	and	tagwise	
dispersions	were	given	 across	 all	 tags.	 Utilising	 both	 scaled	 tag	 counts	 and	 estimated	
dispersions,	negative	binomial	generalised	linear	models	(GLMs)	were	fit	for	each	tag.	All	





Identified	 KEGG	 pathway	 tags	 were	 grouped	 by	 whether	 they	 represented	 the	 total	
abundance	of	a	pathway	across	all	species	in	which	it	was	detected,	or	the	abundance	of	
a	 pathway	 in	 a	 single	 species.	 In	 all	 cases	where	 total	 abundance	 of	 a	KEGG	pathway	
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across	 all	 species	 was	 significantly	 differentially	 expressed,	 cases	 of	 significant	
differential	expression	of	this	same	pathway	in	individual	species	were	identified.	














ACTCCTACGGGAGGCAGCAGT,	 reverse	 primer	 sequence:	 ATTACCGCGGCTGCTGGC)	
(Hartman	 et	 al.,	 2009).	 The	 known	 E.	 faecalis	 JH2-2	 genome	 size	 and	 DNA	 sample	
concentration	were	used	 to	 calculate	bacterial	 copy	number	within	 this	genomic	DNA	
sample	and	in	each	of	the	10-fold	E.	faecalis	JH2-2	dilutions.	These	values	were	used	to	







3.1 Enteral nutrition stringency and duration affect completion 






treatment,	 as	 opposed	 to	 post-treatment	 follow-up.	 The	 substantial	 reduction	 in	




3.2 Mock community standards confirm data reliability 
To	 test	 the	reliability	of	 taxonomic	assignment	 to	16S	rRNA	gene	 sequences,	both	 the	
passage	 of	 sequences	 through	 the	dada2	 pipeline,	 and	 the	 taxonomic	 assignment	 of	
mock	microbial	communities	of	known	composition	were	assessed.	Minimal	sequence	





The	 observed	 taxonomic	 composition	 of	 each	 of	 the	 3	 ZymoBIOMICS	 Microbial	
Community	DNA	Standards	was	then	compared	to	the	expected	taxonomic	composition,	
as	 specified	 by	 the	 manufacturers	 (Figure	 S3;	 Zymo	 Research).	 This	 comparison	
demonstrates	 that	 observed	 species	 abundances	within	 all	 3	 tested	mock	 community	
samples	resemble	expected	species	abundances	(Spearman’s	*	>	0.83	 in	all	cases;	p	<	









3.3 Gut microbiome alpha diversity 






test).	 This	 reduction	 in	 CD	 patient	 stool	 alpha	 diversity	 suggests	 a	 corresponding	
reduction	 in	 gut	microbiome	 alpha	 diversity.	 The	 ubiquity	 of	 these	 results	 across	 all	





























































3.3.2 Enteral nutrition does not change alpha diversity 








Wilcoxon	 rank	 sum	 test),	 while	 the	 CD	 patients	 of	 the	 PEN	 group	 had	 significantly	






the	 healthy	 controls	 by	 all	 3	 utilised	measures	 (observed	 species	 richness	 p	 <	 0.001,	
Shannon	index	p	<	0.01,	Gini-Simpson	p	<	0.05;	Wilcoxon	rank	sum	test),	while	the	PEN	








After	 EN	 treatment,	 both	 the	 EEN	 and	 PEN	 groups	 had	 significantly	 reduced	 alpha	
diversity	relative	to	the	healthy	controls	when	quantified	by	observed	species	richness	
(EEN	p	<	0.05,	PEN	p	<	0.01;	Wilcoxon	rank	sum	test),	but	not	by	Shannon	index	or	Gini-
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3.5 Gut microbiome beta diversity 






people.	 There	were	 no	 significantly	 heterogeneous	 cluster	 dispersions	when	 samples	
were	 clustered	 by	 disease	 state,	 with	 any	 utilised	 measure	 (p	 >	 0.05	 in	 all	 cases;	
betadisper	permutation	test	of	group	dispersion	homogeneity).	Clustering	of	samples	
by	 disease	 state	 was	 significant	 when	 beta	 diversity	 was	 quantified	 by	 all	 utilised	
measures	(p	<	0.01	in	all	cases;	adonis	PERMANOVA).	
As	stool	samples	collected	before	EN	treatment	can	be	clustered	by	disease	state,	 this	
suggests	 that	 the	gut	microbiomes	of	CD	patients	differ	 from	 those	of	healthy	people.	
PERMANOVA	analysis	of	clustering	identifies	significant	differences	in	cluster	centroid	
and	 dispersion.	 Because	 there	 is	 no	 significant	 heterogeneity	 in	 cluster	 dispersion,	
centroid	 location	must	 contribute	 to	 the	 significant	differences	observed	with	disease	
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state,	 indicating	 true	 differences	 in	 gut	 microbiome	 composition	 between	 clusters.	
Analysis	of	PERMANOVA	R2	values	(Table	S4)	shows	that	these	values	are	low,	indicating	
that	 variation	 with	 disease	 state	 represents	 a	 small	 amount	 of	 overall	 community	
variation.	While	this	compositional	change	effect	size	is	small,	it	remains	significant	with	




Figure	4.	Prior	 to	EN	 treatment,	 the	gut	microbiomes	of	CD	patients	differ	 from	
those	of	healthy	people.	NMDS	ordination	of	all	pre-treatment	stool	samples	from	the	
EEN,	PEN,	and	healthy	control	groups.	Samples	are	grouped	by	disease	state.	Diamonds	
represent	 group	 centroids,	 and	 ellipses	 represent	 95%	 CI.	 Groups	 are	 compared	 by	



























3.5.2 The gut microbiome changes with exclusive enteral nutrition 




PEN	 was	 not	 disruptive	 to	 the	 gut	 microbiomes	 of	 CD	 patients.	 Beta	 diversity	 was	
quantified	by	Bray-Curtis	dissimilarity	(Figures	5A,	6A,	7A),	weighted	UniFrac	distance	
(Figures	5B,	6B,	7B),	and	unweighted	UniFrac	distance	(Figures	5C,	6C,	7C).		
There	 were	 no	 significantly	 heterogeneous	 cluster	 dispersions	 when	 samples	 were	
clustered	by	whether	they	were	collected	before,	during,	or	after	EN,	in	any	group,	with	
any	 utilised	measure	 (p	 >	 0.05	 in	 all	 cases;	betadisper	 permutation	 test	 of	 group	
dispersion	 homogeneity).	 Clustering	 of	 samples	 by	 whether	 they	 were	 taken	 before,	
during,	or	 after	 EN	was	 significant	 in	 the	 EEN	 and	 healthy	 control	 groups	when	 beta	
diversity	was	quantified	by	Bray-Curtis	dissimilarity	and	weighted	UniFrac	distance	(p	<	
0.01	in	all	cases;	adonis	PERMANOVA),	but	not	by	unweighted	UniFrac	distance	(p	>	


















suggests	 that	 these	 alterations	 are	 temporary,	 and	 the	 gut	 microbiomes	 of	 both	 CD	
patients	 and	 healthy	 people	 rebound	 after	 treatment.	 The	 lack	 of	 significant	 cluster	
















Diamonds	 represent	 group	 centroids,	 and	 ellipses	 represent	 95%	 CI.	 Groups	 are	
compared	 by	 PERMANOVA,	 and,	 where	 appropriate,	 pairwise	 PERMANOVA	 analysis.	
Beta	 diversity	 was	 quantified	 by	 A)	 Bray-Curtis	 dissimilarity	 (stress	 =	 0.158;	





























CI.	 Groups	 are	 compared	 by	 PERMANOVA,	 and,	 where	 appropriate,	 pairwise	





























to	 treatment.	 Diamonds	 represent	 group	 centroids,	 and	 ellipses	 represent	 95%	 CI.	
Groups	are	compared	by	PERMANOVA,	and,	where	appropriate,	pairwise	PERMANOVA	
analysis.	Beta	diversity	was	quantified	by	A)	Bray-Curtis	dissimilarity	 (stress	=	0.185;	



































patients,	 and	 17	 species	 within	 samples	 collected	 from	 healthy	 controls.	 In	 the	 CD	








Clostridium	 nexile	 and	 Clostridium	 symbiosum.	 Of	 the	 11	 perturbed	 Clostridia	 class	
species,	5	were	significantly	reduced	during	EEN,	5	were	significantly	increased	during	
EEN,	and	1,	C.	symbiosum,	was	not	significantly	altered	during	EEN,	but	was	significantly	
reduced	 after	 EEN.	 Other	 species	 perturbed	 by	 EEN	 belonged	 to	 the	 Actinobacteria,	
Bacteroidia,	 Negativicutes,	 Betaproteobacteria,	 and	 Gammaproteobacteria	 classes.	
Species	within	the	Actinobacteria	and	Bacteroidia	classes	displayed	consistent	patterns	
of	 disturbance	 between	 CD	 patients	 and	 healthy	 controls,	 while	 species	 in	 the	
Negativicutes,	Betaproteobacteria,	and	Gammaproteobacteria	classes	did	not.	The	non-




CD	 patients	 and	 healthy	 people,	 only	 C.	 symbiosum,	 E.	 coli,	 and	 the	 unclassified	
Acidaminococcus	and	Ralstonia	species	were	significantly	different	before	EEN	treatment.	
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C.	 symbiosum	 and	 E.	 coli	 both	 had	 significantly	 increased	 abundances	 in	 CD	 patients	
relative	to	healthy	people	(C.	symbiosum	fold-change	=	8.47,	p	<	0.001;	E.	coli	fold-change	
=	6.53,	p	<	0.01),	while	the	unclassified	Acidaminococcus	and	Ralstonia	species	both	had	





decrease	 in	 CD	 patient	 E.	 coli	 abundance,	 alongside	 increase	 in	 healthy	 control	 C.	







species	 returning	 to	 their	 pre-treatment	 states.	 The	 association	 between	 species	with	
variable	abundances	between	CD	patients	and	healthy	controls	and	variable	responses	to	
EEN	 suggests	 that	 the	 starting	 composition	 of	 the	 gut	microbiome	 is	 likely	 to	 play	 a	
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3.7 Gut microbiome functionality 





pathways,	 only	 the	 total	 abundances	 of	 the	 KEGG	 pathways	 ko02030	 (bacterial	
chemotaxis),	ko02040	(flagellar	assembly),	and	ko05146	(amoebiasis)	were	significantly	











0.01;	Wilcoxon	 rank	sum	 test;	Figures	9B	–	9D).	There	were	no	significant	 changes	 in	
relative	 abundance	 of	 any	 tested	 KEGG	 pathway	 from	 pre-treatment	 state	 to	 after	
treatment	(p	>	0.05	in	all	cases;	Wilcoxon	rank	sum	test;	Figures	9B	–	9D).	
The	 changes	 in	 KEGG	 pathway	 abundance	 observed	 here	 indicate	 that	 the	 genetic	
functional	capacity	of	the	gut	microbiome	changes	with	EEN.	This	is	likely	to	affect	the	
role	 that	 the	 gut	microbiome	 plays	within	 the	 host.	 These	 changes	 reflect	 previously	
observed	changes	in	gut	microbiome	taxonomy	with	EEN,	demonstrating	that	the	impact	
of	EEN	is	 transient,	and	greater	 in	healthy	controls	 than	CD	patients.	While	significant	
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Figure	 9.	 EEN	 alters	 gut	 microbiome	 genetic	 pathway	 abundance.	 Showing	
abundance	 of	 all	 KEGG	 pathways	 undergoing	 significant	 perturbance	 during	 EEN	






3.7.2 Clostridia drive gut microbiome functionality changes 
To	 identify	 bacterial	 species	 contributing	 to	 the	 observed	 changes	 in	gut	microbiome	
functionality	 over	 EEN,	 the	 abundances	 of	 KEGG	 pathways	 ko02030	 (bacterial	
chemotaxis),	 ko02040	 (flagellar	 assembly),	 and	 ko05146	 (amoebiasis)	 in	 associated	
bacterial	species	were	quantified	in	WGS	data	from	stool	samples	collected	from	the	EEN	




treatment	 state,	 either	 during	or	 after	 treatment,	 and	with	 an	 abundance	 fold-change	
greater	 than	1.5,	 are	 shown	 in	Figure	10	 (Wilcoxon	 rank	 sum	 test;	p	<	0.05	 indicates	
significance).	This	differs	from	changes	to	total	KEGG	pathway	abundance	(Figure	9),	as	
KEGG	pathway	abundance	has	here	been	stratified	by	the	bacterial	species	in	which	the	











of	 these	 linked	 KEGG	 pathways	were	 typically	 consistent	with	 each	 other	 at	 all	 time	
points.	The	single	exception	to	this	occurred	 in	Eubacterium	eligens,	where,	 in	 the	gut	




samples	 collected	 from	CD	patients,	 and	16	species-associated	KEGG	pathways	within	
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samples	 collected	 from	 healthy	 controls.	 Of	 the	 20	 total	 species-associated	 KEGG	
pathways	significantly	perturbed	by	EEN,	7	displayed	dissimilar	patterns	of	disturbance	
between	the	CD	patients	and	the	healthy	controls,	consisting	of	KEGG	pathways	from	the	
species	 E.	 eligens,	 Eubacterium	 siraeum,	 unnamed	 Lachnospiraceae	 sp.	 1	 4	 56FAA,	
Roseburia	hominis,	and	Flavonifractor	plautii.	Of	the	species-associated	KEGG	pathways	
significantly	perturbed	with	EEN	in	CD	patients,	8	were	significantly	reduced	and	3	were	
significantly	 increased	 during	 EEN,	 while	 2	 were	 significantly	 reduced	 and	 3	 were	
significantly	increased	after	EEN.	Of	the	species-associated	KEGG	pathways	significantly	
perturbed	 with	 EEN	 in	 healthy	 people,	 13	 were	 significantly	 reduced	 and	 3	 were	
significantly	increased	during	EEN,	while	none	were	significantly	altered	after	EEN.	
The	clear	link	between	alteration	of	KEGG	pathway	abundance	and	associated	Clostridia	
class	 species	 observed	 here	 indicates	 that	 EEN	 alters	 gut	 microbiome	 functionality	
through	perturbation	of	gut	Clostridia.	This	can	be	observed	in	the	gut	microbiomes	of	
both	 CD	patients	 and	 healthy	 people,	with	 some	differences	 in	 response,	 and	 a	more	
lasting	effect	observed	in	CD	patients.	While	the	response	to	EEN	is	not	universal	across	
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3.8 Gut acetate and butyrate are reduced during exclusive 
enteral nutrition 
To	 test	 for	 changes	 to	 gut	 SCFA	 availability	 during	 EEN,	 gas	 chromatography	 was	
performed	on	EEN	and	healthy	control	group	stool	samples	to	determine	concentrations	
of	the	SCFAs	acetate,	butyrate,	isobutyrate,	isovalerate,	propionate,	and	valerate	(Figure	
11).	 Stool	 concentrations	 of	 both	 acetate	 and	 butyrate	 decreased	 during	 EEN,	 then	
rebounded	after	EEN.	In	the	CD	patients	of	the	EEN	group,	there	was	a	significant	increase	
in	 butyrate	 concentration	 from	 during	 EEN	 treatment	 to	 after	 treatment	 (p	 <	 0.05;	
Wilcoxon	rank	sum	test;	Figure	11C).	There	were	no	significant	changes	 in	CD	patient	
butyrate	 concentration	 from	 either	 before	 to	 during	 treatment,	 or	 before	 to	 after	
treatment	(p	>	0.05	 in	both	cases;	Wilcoxon	rank	sum	test).	There	were	no	significant	
changes	in	the	concentrations	of	any	of	the	other	tested	SCFAs	in	CD	patients	over	EEN	
treatment	 (p	 >	 0.05	 in	 all	 cases;	 Kruskal-Wallis	 test;	 Figures	 11B,	 11D	 –	 11G).	 In	 the	
healthy	controls,	there	was	a	significant	reduction	in	the	concentrations	of	both	acetate	
and	 butyrate	 from	 before	 to	 during	 treatment	 (acetate	 p	 <	 0.01,	 butyrate	 p	 <	 0.001;	
Wilcoxon	rank	sum	test;	Figures	11B,	11C).	There	was	then	a	significant	increase	in	the	
concentrations	 of	 both	 acetate	 and	 butyrate	 in	 the	 healthy	 controls	 from	 during	
treatment	to	after	treatment	(p	>	0.01	in	both	cases;	Wilcoxon	rank	sum	test).	There	were	





Stool	 concentrations	of	both	 isobutyrate	and	 isovalerate	prior	 to	EEN	 treatment	were	
significantly	reduced	in	CD	patients	relative	to	healthy	controls	(p	<	0.05	in	both	cases;	








and	 butyrate	 by	 the	 intestinal	 epithelia	 may	 be	 altered	 during	 EEN	 treatment,	 thus	
altering	the	amount	of	these	SCFAs	remaining	in	the	stool.	Whether	changes	in	acetate	
and	butyrate	concentration	occur	due	to	one	of	these	mechanisms,	or	a	combination	of	
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Figure	 11.	 EEN	 alters	 the	 concentration	 of	 SCFAs	 present	 in	 the	 gut.	 SCFA	
concentrations	 observed	 in	 participant	 stool	 samples.	 Showing	 A)	 pre-treatment	
concentration	of	all	tested	SCFAs,	or	concentration	over	EEN	treatment	of	B)	acetate,	C)	





Observation	 of	 both	 CD	 patients	 and	 healthy	 controls	 clearly	 demonstrates	 that	 EEN	
alters	the	gut	microbiome,	and	this	change	may	be	responsible	for	the	reduction	in	CD	
symptoms	observed	with	EN	treatment.	These	alterations	include	changes	to	community	
structure,	 taxonomy,	 genetic	 functional	 capacity,	 and	 metabolic	 output.	 These	
observations	 may	 allow	 a	 better	 understanding	 of	 CD	 aetiology,	 and	 a	 better	
understanding	of	how	CD	can	be	treated.	
4.1 Exclusive enteral nutrition has greater effect than partial 
enteral nutrition 






healthy	 control	 groups	 (21	 and	 17	 participants	 respectively).	 As	 such,	 the	 gut	
microbiomes	of	CD	patients	within	the	PEN	group	may	be	altered	in	a	small	way,	but	the	
small	 number	 of	 samples	 may	 not	 allow	 sufficient	 power	 to	 detect	 these	 changes.	
Therefore,	it	is	impossible	to	determine	the	true	impact	of	PEN	treatment	on	CD	patients	
without	a	greater	number	of	samples.	While	little	information	can	be	gained	from	the	PEN	
group,	 both	 the	 EEN	 and	 healthy	 control	 groups	 offer	 substantial	 insight	 into	 the	
mechanisms	by	which	EN	may	treat	CD.	
4.2 Exclusive enteral nutrition does not remediate drop in alpha 
diversity associated with Crohn’s disease 
This	study	demonstrated	that	CD	gut	microbiome	alpha	and	beta	diversities	differ	from	
those	 of	 healthy	 people,	 prior	 to	 EN	 treatment.	 Here,	 CD	 patients	 have	 reduced	 gut	
microbiome	alpha	diversity	relative	to	healthy	people.	This	reduction	in	alpha	diversity	





EEN,	 this	 indicates	 that	 this	 reduction	 in	 alpha	 diversity	 is	 driven	 primarily	 by	
disturbance	 of	 specific	 taxa,	 as	 opposed	 to	 a	 general	 disruption	 of	 all	 taxa.	 These	
reductions	in	alpha	diversity	have	previously	been	attributed	to	reduced	diversity	within	
the	 Firmicutes	 phylum,	which	 include	 commensal	 species	 belonging	 to	 the	 Clostridia	







occurs	 during	 EEN	 in	 these	 cases	 (Gerasimidis	 et	 al.,	 2014).	 Gerasimidis	 et	 al.	 (2014)	



















CD	 gut	 microbiome	 alpha	 diversity	 with	 their	 use	 is	 the	 result	 of	 a	 reduction	 in	 the	
inflammatory	 response	 at	 the	 intestinal	 epithelia	 (Simon	 et	 al.,	 2016).	 This	 further	
suggests	that	the	reduction	in	gut	microbiome	alpha	diversity	that	occurs	with	CD	may	





4.3 Exclusive enteral nutrition alters gut microbiome 
composition 
Analysis	 of	 gut	 microbiome	 beta	 diversity	 in	 this	 study	 indicates	 significant	 gut	
microbiome	 changes,	 both	 between	 CD	 patients	 and	 healthy	 people,	 and	 over	 EEN	
treatment	 in	 both	 groups.	 While	 substantial	 variation	 in	 both	 healthy	 and	 CD	 gut	




CD	aetiology	(Backhed	et	 al.,	2012;	Douglas	et	al.,	2018;	Pascal	 et	al.,	2017;	Vila	et	 al.,	
2018;	Zuo	and	Ng,	2018).	
The	 gut	 microbiomes	 of	 both	 CD	 patients	 and	 healthy	 people	 are	 observed	 here	 to	
differentiate	with	EEN	treatment,	then	rebound	to	approximately	their	initial	state	after	
treatment.	This	pattern	was	observed	in	both	groups	when	beta	diversity	was	quantified	
by	 both	 Bray-Curtis	 dissimilarity	 and	 weighted	 UniFrac	 distance,	 but	 not	 when	 beta	
diversity	 was	 quantified	 by	 unweighted	 UniFrac	 distance.	 With	 similar	 patterns	 of	
differentiation	and	rebound	observed	in	the	gut	microbiomes	of	both	the	CD	patients	of	
the	EEN	group,	and	the	healthy	controls,	it	appears	that	EEN	alters	the	gut	microbiome	
by	 similar	 mechanisms,	 regardless	 of	 disease	 state.	 These	 alterations	 can	 be	 better	
understood	when	the	different	beta	diversity	metrics	used	here	are	considered.	













microbiome	 with	 EEN	 involve	 minimal	 species	 gains	 or	 losses,	 but	 instead	 involve	
reordering	of	the	abundances	of	the	species	present.	Overall,	analysis	using	these	3	beta	





cluster	 PERMANOVA	 R2	 values	 indicates	 that	 EEN	 has	 a	 greater	 impact	 on	 the	 gut	
microbiomes	of	healthy	people,	relative	to	CD	patients.	This	can	be	seen	in	a	substantially	
greater	differentiation	with	the	onset	of	EEN	treatment	in	the	healthy	control	group.	This	
difference	 in	 response	may	be	due	 to	differences	between	 the	gut	microbiomes	of	CD	
patients	and	healthy	people	that	exist	prior	to	EN	treatment.	
4.4 Exclusive enteral nutrition alters gut microbiome taxonomy 
Observed	changes	 in	 the	abundance	of	 individual	 species	 reflected	 the	 changes	 in	gut	
microbiome	beta	diversity	previously	observed	in	this	study.	Here,	the	gut	microbiome	
again	differentiates	with	EEN	treatment,	and	partially	rebounds	afterwards.	This	can	be	
observed	 in	 the	 primarily	 transient	 changes	 that	 occur	 in	 the	 abundances	 of	 the	
perturbed	species.	An	increased	response	to	EEN	treatment	in	the	gut	microbiomes	of	
healthy	 people,	 relative	 to	 those	 of	 CD	patients,	 is	 also	observable,	with	 an	 increased	




As	 Clostridia	 class	 species	 normally	 make	 up	 between	 10%	 and	 40%	 of	 the	 gut	
microbiome,	this	appears	to	be	a	substantial	overrepresentation	(Lopetuso	et	al.,	2013).	
Alteration	 of	 abundances	 of	 different	 Clostridia	 families	with	 EEN	has	 been	 observed	
previously,	although,	as	observed	in	this	study,	the	response	of	these	taxa	to	EEN	varies	
between	species	(Kaakoush	et	al.,	2015;	MacLellan	et	al.,	2017;	Schwerd	et	al.,	2016).	
Species	 perturbed	 during	 EEN	 predominantly	 show	 similar	 responses	 between	 CD	
patients	and	healthy	people.	Where	a	dissimilar	response	is	observed,	this	can	frequently	
be	associated	with	significant	differences	 in	pre-treatment	abundance	between	the	CD	
patients	 and	 healthy	 people.	 Pre-treatment	 E.	 coli	 abundance	 is	 7-fold	 higher	 in	 CD	
patients	relative	to	healthy	people,	and	is	reduced	during	EEN	in	CD	patients,	but	remains	
largely	unaffected	in	healthy	people.	The	pre-treatment	abundances	of	the	unclassified	
Acidaminococcus	 and	 Ralstonia	 species	 are	 respectively	 9-fold	 and	 6-fold	 higher	 in	
healthy	 people	 relative	 to	 CD	 patients,	 and	 are	 both	 reduced	 during	 EEN	 in	 healthy	
people,	but	 remain	 largely	unaffected	 in	CD	patients.	This	 suggests	 that,	while	EEN	 is	












2004;	Mylonaki	 et	 al.,	 2005;	Swidsinski	 et	 al.,	 2002).	The	 increased	C.	 symbiosum	 and	
reduced	 Acidaminococcus	 and	 Ralstonia	 species	 abundances	 observed	 here	 in	 pre-









to	 contribute	 to	 disease,	 and	 those	 that	 are	 likely	 to	 result	 from	 disease,	 which	may	
become	lost	when	microbiome	analysis	is	purely	taxonomic.	
4.5 Exclusive enteral nutrition alters gut microbiome functionality 
4.5.1 Exclusive enteral nutrition alters genetic pathway abundance 
To	determine	how	EEN	alters	the	genetic	functional	capacity	of	the	gut	microbiome,	the	
abundance	of	KEGG	genetic	pathways	was	observed	over	the	course	of	EEN	treatment.	
The	 only	 3	 KEGG	 pathways	 where	 a	 significant	 change	 in	 relative	 abundance	 was	
identified	with	 EEN	 treatment	were	 the	 flagellar	 assembly,	 bacterial	 chemotaxis,	 and	
amoebiasis	pathways.	The	abundance	of	all	of	these	pathways	 in	healthy	controls	was	
reduced	during	EEN,	rebounding	after	treatment.	There	were	no	KEGG	pathways	that	had	
a	 significant	 increase	 in	 abundance	 during	 EEN.	 This	 pattern	 of	 differentiation	 and	
rebound	reflects	previously	observed	changes	to	the	gut	microbiome	with	EEN,	both	to	
community	 structure	 and	 taxonomic	 composition.	 While	 there	 were	 no	 significant	
changes	 in	 the	 relative	 abundance	 of	 these	 pathways	 in	 the	 gut	 microbiomes	 of	 CD	
patients	with	EEN,	 the	same	pattern	of	pathway	reduction	and	rebound	was	observed	
here.	As	all	pathways	that	are	significantly	changed	in	abundance	over	EEN	treatment	are	
also	 significantly	 reduced	 in	 CD	 patients	 prior	 to	 EN	 treatment,	 this	may	 explain	 the	




observed	 are	 not	 significant,	 this	 does	 not	 necessarily	 mean	 they	 are	 not	 clinically	
relevant.	









is	 of	 vastly	 lower	 abundance	 than	 the	 other	 pathways	 detected	 to	 change	 with	 EEN	
treatment,	which	may	indicate	that	the	ko05146	pathway	is	uncommon,	and	potentially	
poorly	 characterised.	 Poor	 pathway	 characterisation	may	 lead	 to	 an	 increased	 risk	of	
incorrect	assignment.	
While	 the	 incorrect	assignment	of	 the	ko05146	pathway	does	cast	some	doubt	on	the	
process	of	KEGG	pathway	assignment	using	HUMAnN2,	it	is	unlikely	that	either	of	the	2	
pathways	 observed	 to	 change	with	 EEN	 have	 been	 incorrectly	 assigned.	 The	 other	 2	
pathways	 were	 both	 consistent	 with	 their	 associated	 bacterial	 species,	 and	 are	 of	
substantially	 higher	 relative	 abundance,	 which	 may	 make	 poor	 characterisation	 less	
likely.	 The	 incorrect	 assignment	 of	 the	 ko05146	 pathway	 does	 not	 influence	 the	
assignment	 of	 bacterial	 species	 names,	 as	 these	 were	 identified	 during	 MetaPhlAn2	
processing,	prior	to	gene	family	assignment	using	HUMAnN2.	
Despite	 the	 incorrect	 assignment	of	 the	ko05146	pathway,	 there	 is	 consistency	 in	 the	
response	of	the	3	perturbed	KEGG	pathways	to	EEN.	This	suggests	that	changes	to	the	
abundance	of	 these	pathways	are	 linked	through	changes	to	 the	abundance	of	related	
taxa.	 Analysis	 of	 species	 associated	 with	 changes	 in	 the	 abundances	 of	 these	 KEGG	







likely	 that	 taxa	 and	 genetic	 pathways	 that	 are	 altered	 in	 the	 gut	 microbiomes	 of	 CD	
patients	 are	 predominantly	 altered	 in	 response	 to	 CD,	 and	 that	 EEN	may	 be	 effective	
















coli,	 and	 Pseudomonas	 aeruginosa	 (Donnelly	 and	 Steiner,	 2002;	 Morris	 et	 al.,	 2009;	
Murthy	et	al.,	2004).	However,	the	basolateral	expression	of	IEC	TLR5	typically	protects	
commensal	flagellated	bacterial	species	from	a	TLR5-mediated	inflammatory	response,	








CD	 patients	 prior	 to	 EN	 treatment.	 It	 is	 possible	 that	 the	 CD	 inflammatory	 response	
targets	 flagellated	 bacteria,	 thus	 decreasing	 the	 relative	 abundance	 of	 the	 flagellin	
assembly	pathway.	
The	connection	between	CD	and	the	bacterial	chemotaxis	pathway	is	less	clear	than	that	
with	 the	 flagellar	 assembly	 pathway.	 However,	 it	 is	 possible	 that	 changes	 to	 the	
abundance	 of	 the	 bacterial	 chemotaxis	 pathway	 with	 EEN	 reflect	 changes	 to	 the	
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abundance	of	taxa	that	are	also	associated	with	the	flagellar	assembly	pathway.	To	clarify	
the	 roles	 of	 the	 flagellar	 assembly	 and	 bacterial	 chemotaxis	 pathways	within	 the	 gut	
microbiomes	of	CD	patients,	the	species	that	contribute	to	the	changes	in	abundance	of	
these	pathways	were	investigated.	
4.6 Clostridia class species alter gut microbiome functionality 
4.6.1 Clostridia class species account for genetic changes within the gut 
microbiome 
All	of	the	bacterial	species	linked	to	the	genetic	changes	that	occur	in	the	gut	microbiome	
with	EEN	 treatment	belonged	 to	 the	Clostridia	 class.	As	expected	 from	analysis	of	 the	
consistent	 KEGG	 pathway	 abundance	 changes	 with	 EEN,	 there	 is	 substantial	 overlap	
between	the	species	that	contribute	to	the	changes	in	abundance	of	these	pathways.	As	
expected,	 where	 changes	 in	 pathway	 abundance	 were	 linked	 to	 the	 same	 bacterial	
species,	 these	 changes	 typically	 reflect	 each	 other.	 This	 supports	 the	 hypothesis	 that	
changes	 in	 the	 relative	 abundance	 of	 both	 the	 bacterial	 chemotaxis	 and	 unknown	
pathways	may	be	resultant	from	changes	to	the	abundance	of	flagellated	bacteria.	The	
single	exception	to	this	occurs	in	E.	eligens,	where	the	abundance	of	the	associated	KEGG	
flagellar	 assembly	 pathway	 (ko02040)	 is	 substantially	 reduced	 during	 EEN	 in	 CD	
patients,	 while	 the	 abundance	 of	 the	 chemotaxis	 pathway	 (ko02030)	 is	 substantially	
increased	during	EEN	 in	CD	patients.	 It	has	previously	been	demonstrated	 that	genes	
associated	with	motility	and	flagellar	assembly	are	non-uniformly	detected	within	the	
genomes	 of	 E.	 eligens,	 which	 may	 explain	 the	 differential	 response	 of	 ko02030	 and	
ko02040	to	EEN	(Neville	et	al.,	2013).	This	suggests	that	flagellated	E.	eligens	are	selected	











intestinal	 epithelial	 cells	 (Anjuwon-Foster	 and	 Tamayo,	 2017).	 Clostridia	 begin	
colonisation	 of	 a	 breastfed	 infant’s	 gut	microbiome	 in	 the	 infant’s	 first	 month	 of	 life	
(Roberts	et	al.,	1992).	With	this	colonisation,	Clostridia	associate	closely	with	the	host’s	











4.6.2 Clostridium cluster XIVa flagellin is associated with Crohn’s disease 
The	Clostridia	 class	 species	 that	 contribute	 to	 EEN-related	 genetic	 changes	 in	 the	 gut	
microbiome	can	be	broadly	phylogenetically	clustered.	The	species	Eubacterium	rectale,	
E.	 eligens,	 Roseburia	 intestinalis,	 R.	 hominis,	 Clostridium	 hathewayi,	 and	 Butyrivibrio	
crossotus	all	belong	to	Clostridium	cluster	XIVa	(Rosero	et	al.,	2016;	Stanton	and	Savage,	
1983;	 Warren	 et	 al.,	 2006;	 Willems	 et	 al.,	 1996).	 The	 species	 E.	 siraeum,	 F.	 plautii,	
Anaerotruncus	colihominis,	and	Ruminococcus	bromii	all	belong	to	Clostridium	cluster	IV	





in	 the	 abundance	 of	 the	 flagellar	 assembly	 pathway.	 Conversely,	 none	 of	 the	 genetic	
change-linked	Clostridium	cluster	IV	species	were	linked	to	changes	in	the	abundance	of	
the	 flagellar	 assembly	 pathway.	 As	 such,	 it	 seems	 likely	 that	 species	 belonging	 to	
Clostridium	 cluster	 XIVa	 contribute	 substantially	 to	 the	 reductions	 in	 total	 flagellar	
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assembly	 that	 occur	 with	 both	 CD	 and	 EEN.	 This	 is	 of	 particular	 interest,	 as	 an	
inappropriate	host	immune	reaction	to	Clostridium	cluster	XIVa	flagellin	has	previously	
been	heavily	implicated	in	CD.		




identified	 antigens,	 flagellins	 from	microbial	 species	 aligning	with	Clostridium	 cluster	
XIVa	were	dominant.	The	XIVa	flagellin	antigens	identified	here	included	CBir1	and	Fla-
X.	 The	 strong	 anti-flagellin	 immune	 response	 occurred	 across	 tested	 mouse	 strains,	
despite	the	differing	mechanisms	by	which	these	strains	are	believed	to	develop	colitis	
(Lodes	et	al.,	2004).	These	include	defects	in	immune	regulation	in	IL-10-null	mice,	and	
impaired	 barrier	 function	 in	Mdr-null	mice	 (Keubler	 et	 al.,	 2015;	 Resta-Lenert	 et	 al.,	
2005).	Further	work	demonstrates	that	even	murine	colitis	induced	by	consumption	of	






patients.	 Here,	 similar	 to	 the	 murine	 studies,	 heightened	 serum	 immunoreactivity	 to	
CBir1	was	observed	in	CD	patients.	While	a	small	degree	of	serum	immunoreactivity	was	
observed	 to	 the	 dissimilar	 Salmonella	 muenchen	 flagellin,	 which	 is	 similar	 to	 E.	 coli	
flagellin,	this	was	not	observed	to	differ	between	CD	patients	and	healthy	controls	(Lodes	
et	al.,	2004).	Serum	anti-CBir1	antibodies	have	also	been	independently	associated	with	








EEN	 treatment	 induces	 are	 dominated	 by	 reductions	 in	 the	 abundance	 of	Clostridium	
cluster	XIVa	 flagellins.	This	 reduction	 follows	 the	 reduction	 in	 flagellar	 assembly	 that	





may	 be	 altered	 in	 CD	patients.	When	 considering	 this,	 the	 ubiquitous	 innate	 immune	
response	to	Clostridium	cluster	XIVa	flagellin	in	colitic	mouse	strains	observed	by	Lodes	
et	al.	(2004),	regardless	of	how	colitis	was	induced,	is	of	particular	interest.	The	primary	
factor	 that	 all	 colitic	 mouse	 strains	 utilised	 here	 would	 have	 in	 common	 would	 be	
impaired	intestinal	epithelia	barrier	function	(Lodes	et	al.,	2004).	As	such,	it	seems	likely	
that	 host	 intestinal	 epithelial	 barrier	 function	 may	 be	 involved	 in	 some	 way	 in	 the	
development	 of	 an	 inappropriate	 host	 immune	 response	 to	 Clostridium	 cluster	 XIVa	
flagellins.	
4.7 Butyrate production induces the tolerance of commensal 




suppresses	 inflammatory	 immune	 responses,	 and	 aids	 in	 tolerance	 to	 the	 Clostridia	
(Omenetti	and	Pizarro,	2015).	
The	 exact	 mechanisms	 by	 which	 commensal	 gut	 microbes	 induce	 colonic	 Treg	 cell	
accumulation	 remain	 unclear,	 but	 the	 presence	 of	 gut	 SCFAs	 has	 been	 proposed	 as	 a	
contributing	factor	(Arpaia	et	al.,	2013;	Furusawa	et	al.,	2013).	Butyrate	produced	by	the	
gut	microbiome	influences	colonic	Treg	cell	development.	Butyrate	can	participate	in	Treg	




receptor	 GPR109a,	 promoting	 DC	 retinoic	 acid	 production,	 and	 subsequent	 Treg	 cell	
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differentiation	 (Singh	 et	 al.,	 2014).	 Beyond	 its	 role	 in	 Treg	 cell	 differentiation,	 in	 vivo	
administration	of	butyrate	has	been	demonstrated	to	directly	supress	pro-inflammatory	






changed	significantly	over	EN	 treatment.	 In	both	 cases,	 the	amount	of	 these	SCFAs	 in	
healthy	 control	 samples	 reflect	 previously	 observed	 patterns	 of	 significant	 reduction,	
then	rebound.	While	neither	acetate	nor	butyrate	was	significantly	changed	between	CD	
patients	 and	 healthy	 controls	 pre-treatment,	 there	 was	 a	 substantial,	 non-significant	
reduction	 in	 the	 amount	 of	 butyrate	 in	 the	 pre-treatment	 CD	 samples	 relative	 to	 the	
healthy	 controls.	 A	 similar	 change	was	 not	 observed	 in	 the	 amount	 of	 pre-treatment	
sample	acetate.	











capable	 of	 reducing	 intestinal	 inflammation	 in	 CD	 patients,	 at	 least	 temporarily	 (Di	
Sabatino	et	al.,	2005).	However,	this	treatment	method	is	unlikely	to	induce	permanent	













species,	 and	 thus	 the	 associated	 CBir1	 and	 Fla-X	 flagellin	 proteins.	 From	 this,	 any	
inappropriate	host	inflammatory	response	to	CBir1	and	Fla-X	is	also	likely	to	be	reduced.	
However,	Clostridium	 cluster	XIVa	 flagellins	are	not	capable	of	causing	CD	in	 isolation.	
Both	CBir1	and	Fla-X	are	present	in	the	gut	microbiomes	of	healthy	people,	and	do	not	








been	demonstrated	 to	be	a	substantial	CD	 risk	 factor	 (Hugot	et	 al.,	 2001;	Ogura	et	 al.,	











innate	 immune	response	to	CBir1	and	Fla-X,	 thus	making	this	 immune	response	more	
challenging	 to	 regulate.	 During	 CD,	 inflammation	 may	 be	 further	 aggravated	 by	
disruption	to	the	intestinal	epithelia.	MacDonald	and	Monteleone	(2005)	hypothesised	
that	increased	epithelial	permeability	with	CD	ulceration	allows	for	increased	passage	of	
microbial	 antigens	 into	 the	 lamina	propria,	 thus	 supporting	an	 inflammatory	 immune	
response.	We	 can	 therefore	 see	 how	host	 genetic	 susceptibility	may	 contribute	 to	 CD	





such,	 directly	 linking	 environmental	 factors	 that	 influence	 the	 gut	microbiome	 to	 CD	
aetiology	 becomes	 challenging.	 However,	 it	 still	 seems	 likely	 that	 any	 environmental	
factor	resulting	in	a	substantially	greater	abundance	of	flagellated	cluster	XIVa	Clostridia	

















































4.9 Exclusive enteral nutrition reduces the abundance of gut 
flagellated bacteria 
While	it	appears	that	the	inflammatory	response	observed	in	CD	patients	directly	targets	
species	expressing	CBir1	and	Fla-X,	 it	 is	unlikely	 that	EEN	 is	 this	specific.	This	 can	be	
observed	 in	the	 impact	 that	EEN	has	on	other	flagellated	bacterial	species	 that	do	not	
express	 CBir1	 and	 Fla-X,	 such	 as	 E.	 coli	 (Lodes	 et	 al.,	 2004).	 While	 changes	 in	 the	
abundance	of	these	species	have	not	been	associated	here	with	changes	in	the	functional	
capacity	of	the	gut	microbiome,	they	may	still	offer	insight	into	the	mechanism	behind	
EEN.	 The	 observed	 increase	 in	 E.	 coli	 abundance	 in	 CD	 patients	 relative	 to	 healthy	
controls	suggests	that	E.	coli	escapes	the	CD	inflammatory	response,	which	is	consistent	
with	 its	 lack	of	expression	of	CBir1	and	Fla-X.	It	 is	possible	 that	 the	targeting	of	other	








reduces	 the	 abundance	 of	 flagellated	 bacterial	 species.	 If	 this	 is	 not	 a	 bioinformatic	
artefact,	this	may	be	through	some	selective	pressure	against	flagellated	bacteria	in	the	
gut	microbiome,	or	through	a	selective	pressure	against	mucosal-associated	bacteria,	as	
non-flagellated,	 non-motile	 bacteria	would	 be	 unable	 to	 efficiently	 associate	with	 the	
mucosa.	With	the	limited	knowledge	available	on	the	mechanisms	through	which	EEN	is	
effective,	it	is	difficult	to	determine	this	from	the	information	available	here.	
The	 final	 notable	 impact	 that	 EEN	 has	 on	 species	 not	 associated	with	 changes	 in	 gut	

















4.10 Potential for novel Crohn’s disease treatments 
An	 understanding	 of	 CD	 aetiology	 potentially	 allows	 for	 the	 development	 of	 novel	
treatments.	While	EEN	treatment	has	a	number	of	strengths,	it	is	not	flawless.	The	bad	
taste	in	the	EEN	formula	results	in	treatment	compliance	rates	that	can	range	as	low	as	





Di	 Sabatino	et	 al.	 (2005)	demonstrated	 that	oral	 administration	of	butyrate	had	 some	
efficacy	 in	 inducing	 short-term	 remission	 in	 CD	patients.	 This	 is	 likely	 to	 be	 effective	




who	 suggested	 that	 butyrate-producing	 bacteria	 may	 be	 supplemented	 into	 the	 gut	






concept	 for	 gut	 microbiome	 supplementation	 with	 butyrate-producing	 bacteria	 as	 a	
potential	CD	treatment,	the	potentially	detrimental	effects	of	these	bacterial	species	was	
not	discussed	here.	When	regarding	this	work	in	the	context	of	both	the	findings	of	this	
study,	 and	 the	 scientific	 literature,	 there	 seems	 to	 be	 a	 strong	 chance	 that	 flagellin	
proteins	of	these	butyrate-producing	species	may	induce	an	inflammatory	response	in	
the	 CD	patient.	However,	 this	 could	 potentially	 be	 avoided	 by	 careful	 selection	of	 the	
butyrate-producing	 species	used	 in	 this	 treatment.	While	Geirnaert	 et	 al.	 (2017)	used	
Clostridia	 class	 species	 belonging	 to	 both	 Clostridium	 clusters	 IV	 and	 XIVa,	 using	
exclusively	 cluster	 IV	 may	 be	 the	 preferable	 methodology.	 To	 date,	 only	 Clostridium	
cluster	 XIVa	 flagellin	 proteins	 have	 been	 identified	 as	 antigens	 likely	 to	 cause	 an	
inflammatory	response	 in	people	genetically	susceptible	 to	CD	(Lodes	et	al.,	2004).	As	
such,	it	is	possible	that	species	belonging	to	Clostridium	cluster	IV	would	be	capable	of	




4.11 Limitations of study 
The	study	performed	here	has	some	limitations.	It	has	been	argued	that,	due	to	greater	
passage	of	lumenal	bacterial	species	into	the	faecal	material	relative	to	mucosal	species,	
stool	 samples	may	 not	 be	 truly	 representative	 of	 the	 gut	microbiome	 (Durban	 et	 al.,	
2011).	 However,	 in	 our	 own	 results,	 the	 vast	 majority	 of	 significant	 changes	 within	
taxonomic	groups	occur	in	those	species	that	associate	closely	with	the	mucosa,	including	
the	 commensal	Clostridia	 species	 implicated	 in	disease	 (Anjuwon-Foster	and	Tamayo,	
2017).	 This	 suggests	 that,	 regardless	 of	 any	 potential	 misrepresentation	 of	 relative	
mucosal	and	lumenal	species	abundance,	changes	to	mucosal-associated	samples	were	
still	detected	to	a	sufficient	extent.	Work	by	Yasuda	et	al.	(2015)	also	demonstrates	that	
faecal	 samples	 are	 highly	 representative	 of	 the	 colonic	 microbiome	 of	 the	 rhesus	
macaque,	suggesting	that	the	use	of	faecal	samples	in	this	study	is	reasonable.	
The	small	size	of	the	tested	group	makes	it	challenging	to	truly	determine	how	PEN	affects	
the	 gut	 microbiome	 of	 CD	 patients.	 No	 significant	 changes	 were	 observed	 with	 this	
treatment	in	this	investigation,	but	this	does	not	necessarily	mean	that	PEN	does	not	alter	
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the	gut	microbiome	at	 all.	To	examine	 this	properly,	 a	 larger	group	would	need	 to	be	
examined,	potentially	similar	 in	size	to	 the	EEN	and	heathy	control	groups.	There	was	
also	suboptimal	compliance	to	the	full	EEN	treatment	within	the	EEN	group.	As	such,	the	











immune	 response	 would	 allow	 insight	 into	 the	 potential	 role	 of	 CBir1	 and	 Fla-X	 in	






recover.	 Oral	 administration	of	 butyrate	 has	 previously	 been	 demonstrated	 to	 induce	
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Treatment	 Patient	 Complete	 Missing	time	
points	
WGS	 SCFA	 qPCR	
CD	 EEN	 2	 Yes	 	 0,	2,	12	 0,	2,	12	 	
3	 Yes	 	 0,	2,	12	 0,	2,	12	 24	
4	 No	 6,	8,	12,	24	 	 	 0,	4	
5	 No	 6,	8,	12,	24	 	 	 0,	4	
6	 Yes	 	 0,	2,	12	 0,	2,	12	 	
7	 Yes	 	 0,	2,	12	 0,	2,	12	 4,	24	
8	 Yes	 	 0,	2,	12	 0,	2,	12	 4,	24	
9	 Yes	 	 0,	2,	12	 0,	2,	12	 4,	24	
10	 Yes	 	 0,	2,	12	 0,	2,	12	 	
11	 No	 4,	6,	8,	12,	24	 	 	 0	
12	 No	 8,	12,	24	 	 	 0,	4	
14	 No	 4,	6,	8,	12,	24	 	 	 0	
15	 No	 4,	6,	8,	12,	24	 	 	 0	
16	 No	 6,	8,	12,	24	 	 	 	
17	 Yes	 	 0,	2,	12	 0,	2,	12	 	
18	 Yes	 	 0,	2,	12	 0,	2,	12	 	
19	 Yes	 	 0,	2,	12	 0,	2,	12	 	
20	 Yes	 	 0,	2,	12	 0,	2,	12	 24	
21	 Yes	 	 0,	2,	12	 0,	2,	12	 	
23	 No	 4,	6,	8,	12,	24	 	 	 	
25	 Yes	 	 0,	2,	12	 0,	2,	12	 24	
PEN	 50	 Yes	 	 	 	 	
51	 Yes	 	 	 	 	
52	 Yes	 	 	 	 	
53	 No	 4	 	 	 	
55	 Yes	 	 	 	 	
56	 Yes	 	 	 	 	
59	 Yes	 	 	 	 	
61	 Yes	 	 	 	 	
62	 Yes	 	 	 	 	
Healthy	 EEN	 201	 Yes	 	 0,	2,	6	 0,	2,	6	 	
202	 Yes	 	 0,	2,	6	 0,	2,	6	 0,	2,	6	
203	 Yes	 	 0,	2,	6	 0,	2,	6	 0,	2,	6	
205	 Yes	 	 0,	2,	6	 0,	2,	6	 	
206	 Yes	 	 0,	2,	6	 0,	2,	6	 	
207	 Yes	 	 0,	2,	6	 0,	2,	6	 	
208	 Yes	 	 0,	2,	6	 0,	2,	6	 	
209	 Yes	 	 0,	2,	6	 0,	2,	6	 	
210	 Yes	 	 0,	2,	6	 0,	2,	6	 	
211	 Yes	 	 0,	2,	6	 0,	2,	6	 0,	2,	6	
212	 Yes	 	 0,	2,	6	 0,	2,	6	 0,	2,	6	
214	 Yes	 	 0,	2,	6	 0,	2,	6	 0,	2,	6	
215	 Yes	 	 0,	2,	6	 0,	2,	6	 0,	2,	6	
216	 Yes	 	 0,	2,	6	 0,	2,	6	 	
217	 Yes	 	 0,	2,	6	 0,	2,	6	 	
218	 Yes	 	 0,	2,	6	 0,	2,	6	 	








Figure	 S1.	 Sample	 rarefaction	 at	 a	 sequencing	depth	of	 15,000	 reads	 allows	 for	
optimal	alpha	diversity	measurement	across	samples.	Observed	species	richness	of	
16S	rRNA	data	from	all	available	stool	samples,	rarefied	to	increasing	sequencing	depths.	




































































































































Removed low-quality reads                         Removed "untrue" ASVs             Removed unmerged reads

















Figure	 S3.	 16S	 rRNA	 sequencing	 and	 subsequent	 taxonomic	 assignment	 reflects	
expected	composition	of	mock	bacterial	communities.	Relative	abundance	of	genera	
found	in	ZymoBIOMICS	Microbial	Community	DNA	Standards,	against	expected	relative	
abundances	 defined	 by	 the	 manufacturers	 (Zymo	 Research),	 observed	 in	 A)	 Mock	 1	
(Spearman’s	!	=	0.859;	p	<	0.0001),	B)	Mock	2	(Spearman’s	!	=	0.859;	p	<	0.0001),	or	C)	













































function	adonis.	 Showing	 R2	 values	 for	adonis	 tests	 comparing	 disease	 state	 and	
treatment	time	within	the	pre-treatment,	EEN,	PEN,	and	healthy	control	groups.	Bold	R2	
values	indicate	a	significant	adonis	test	(**	p	<	0.01).	
